Spironolactone

Combining PRP with pharmacological support during FUE hair transplantation significantly improves follicle survival, growth rates, and hair strength compared to pharmacological support alone.

Standard treatments like topical minoxidil and oral finasteride are established, while newer modalities like PRP, LLLT, and oral minoxidil show encouraging results but lack standardized protocols.

The review discusses various promising topical, oral, and energy-based therapies, noting growing evidence for their efficacy in treating hair loss.

Topical minoxidil and oral anti-androgens are the primary treatments aimed at halting progression and promoting cosmetically acceptable hair regrowth in female pattern hair loss.

Topical minoxidil shows moderate efficacy in increasing hair regrowth and hair count in women with FPHL, with no clear advantage of 5% over 2% concentration; oral finasteride 1 mg is not more effective than placebo; low-level laser therapy may increase hair count but clinical relevance is uncertain.

Current treatments (minoxidil, finasteride) offer limited and non-permanent benefits; hair transplantation is the only permanent option, while other off-label agents and laser therapies are commonly used despite modest or inconsistent efficacy.

Treatments such as topical minoxidil and 5‑alpha reductase inhibitors (finasteride, dutasteride) can slow hair loss progression and promote regrowth, but continuous use is required to maintain benefit.